Coeptis Therapeutics Holdings, Inc. COEP
Set alert
10.99 USD 0.00 0.00%
As of Jul 2, 3:59 PM ET
10.81 Day range 11.99
0.131 52-week range 0.87
- YTD
- -22.88%
- 1 year
- -11.87%
- Open
- 11.76
- Prev close
- 10.99
- Mkt cap
- 5.74M
- Vol
- 408.20K
- Avg vol
- 517.73K
- EPS
- -0.28
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.81
- High
- 11.99
- Forward P/E
- -0.82
- Beta
- -0.94
- Short ratio
- 0.40
- Inst. own
- 4.28%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.19768
- 200-d avg
- 0.25673
- 1y target
- 0.00
Ownership
Held by insiders 18.53%
Held by institutions 4.28%
Float held by institutions 5.25%
Institutions 17
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Creative Planning | 1.57% | 645,104 | 90.06K | Sep 29, 2024 |
| Meteora Capital, LLC | 1.09% | 446,251 | 62.30K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.37% | 153,781 | 21.47K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.27% | 111,338 | 15.54K | Sep 29, 2024 |
| Vanguard Group Inc | 0.25% | 100,759 | 14.06K | Sep 29, 2024 |
| Cambridge Investment Research Advisors Inc. | 0.14% | 56,149 | 7.84K | Sep 29, 2024 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.25% | 100,759 | 14.06K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.24% | 99,301 | 13.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 22,919 | 3.20K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 20,353 | 2.84K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,848 | 816 | Oct 30, 2024 |
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CALISE CHRIS | Director | Purchase | Aug 22, 2023 | 1,464,900 |
| COCHRAN CHRISTOPHER P | Director | Purchase | Jan 4, 2024 | 37,000 |
| COGLEY BRIAN | Chief Financial Officer | Purchase | Jan 9, 2024 | 30,000 |
| DESILVA TARA | Director | Purchase | Jan 11, 2024 | 32,266 |
| MEHALICK DAVID | Chief Executive Officer | Purchase | Jan 7, 2024 | 2,782,620 |
| SALKIND GENE | Director | Purchase | Jan 4, 2024 | 316,740 |